Protein–Ligand Interactions in Cardiometabolic Drug Targets: Focus on Weight Loss and Cardioprotection
Molecules · 30.10.2025 · 30 (21) · 4240
DOI: 10.3390/molecules30214240 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 30.10.2025. Verfasst von Errikos Petsas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 11571 Athens, Greece. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Weight Loss, Cardiotonic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 208 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cardiometabolic diseases (CVDs) are the leading cause of premature mortality and disability worldwide, arising from of cardiovascular and metabolic dysregulation. This review focuses on six critical therapeutic targets established in cardiometabolic regulation: GLP-1R, GIPR, FGFR1/β-Klotho, PCSK9, NF-κB, and the NLRP3 inflammasome. Drawing on curated structural datasets, we analyze the mechanisms of action and map key binding domain features that govern ligand efficacy and specificity. Dual GLP-1R/GIPR agonists, such as tirzepatide, demonstrate superior outcomes in glycemic control and weight reduction. Concurrently, inhibiting PCSK9, NF-κB, and NLRP3 helps to lower cholesterol and reduce harmful inflammation, offering cardioprotection. Structural analysis across these targets reveals complementary motifs (aromatic, hydrophobic, and polar residues). These insights guide the rational design of next-generation multi-target ligands (molecules capable of modulating two or more biological targets involved in related disease pathways, producing integrated therapeutic effects). Such integrated agents are promising for providing combined cardiovascular and metabolic benefits, thus reducing the risks associated with complex therapeutic drug combinations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 11571 Athens, Greece.
- Center for Interdisciplinary Biosciences, Technology and Innovation Park, P.J. Safarik University in Kosice, 040 01 Kosice, Slovakia.
- 3rd Department of Cardiology, Thoracic Diseases General Hospital Sotiria, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
ORCID-Profile: Errikos Petsas, Despoina P Kiouri, Nikitas Georgiou, Thomas Mavromoustakos
Zitieren
APA
Petsas, E., Kiouri, D. P., Georgiou, N., Siasos, G., Mavromoustakos, T., & Chasapis, C. T. (2025). Protein–Ligand Interactions in Cardiometabolic Drug Targets: Focus on Weight Loss and Cardioprotection. Molecules, 30(21), 4240. https://doi.org/10.3390/molecules30214240
Vancouver
Petsas E, Kiouri DP, Georgiou N, Siasos G, Mavromoustakos T, Chasapis CT. Protein–Ligand Interactions in Cardiometabolic Drug Targets: Focus on Weight Loss and Cardioprotection. Molecules. 2025;30(21):4240. doi:10.3390/molecules30214240
BibTeX
@article{Petsas2025,
author = {Petsas, Errikos and Kiouri, Despoina P and Georgiou, Nikitas and Siasos, Gerasimos and Mavromoustakos, Thomas and Chasapis, Christos T},
title = {Protein–Ligand Interactions in Cardiometabolic Drug Targets: Focus on Weight Loss and Cardioprotection},
journal = {Molecules},
year = {2025},
volume = {30},
number = {21},
pages = {4240},
doi = {10.3390/molecules30214240}
}
EUVIMED